drugset / Trial / NCT05362292
TReating Incontinence for Underlying Mental and Physical Health
Phase 4
Recruiting
270 enrolled
University of California, San Francisco
National Institute on Aging (NIA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.
Timeline
- Start
- 2022-10-04
- Primary completion
- 2027-05-02
- Completion
- 2027-08-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mirabegron | Other / unclassified | 25 mg | Oral |
| Comparator | Mirabegron | Other / unclassified | 50 mg | Oral |
| Comparator | Tolterodine | Small molecule | 2 mg | Oral |
| Comparator | Tolterodine | Small molecule | 4 mg | Oral |